Unresolved priapism secondary to tamsulosin

Tamsulosin is the most potent adrenergic alpha-1 antagonist used for the treatment of benign prostatic hyperplasia. Priapism has been reported rarely in patients taking Prazosin, Doxazosin and Terazosin. We describe an otherwise healthy man with recurrent and then persistent unresolved priapism after the use of tamsulosin. Initial treatment consisted of aspiration and intracavernosal irrigation of iced saline and vasoconstrictive agent, but in vain. We then performed Winters procedure but that too failed and the priapism persisted. Health-care professionals should inform all patients taking such medications about rare but possible serious adverse effects.

TNFα-mediated Hsd11b1 binding of NF-κB p65 is associated with suppression of 11β-HSD1 in muscle

The activity of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive cortisone (11-dehydrocorticosterone (11-DHC)) (in mice) into the active glucocorticoid (GC) cortisol (corticosterone in mice), can amplify tissue GC exposure. Elevated TNFα is a common feature in a range of inflammatory disorders and is detrimental to muscle function in diseases such as rheumatoid arthritis and chronic obstructive pulmonary disease. We have previously demonstrated that 11β-HSD1 activity is increased in the mesenchymal stromal cells (MSCs) by TNFα treatment and suggested that this is an autoregulatory anti-inflammatory mechanism. This upregulation was mediated by the P2 promoter of the Hsd11b1 gene and was dependent on the NF-κB signalling pathway. In this study, we show that in contrast to MSCs, in differentiated C2C12 and primary murine myotubes, TNFα suppresses Hsd11b1 mRNA expression and activity through the utilization of the alternative P1 promoter. As with MSCs, in response to TNFα treatment, NF-κB p65 was translocated to the nucleus. However, ChIP analysis demonstrated that the direct binding was seen at position -218 to -245 bp of the Hsd11b1 gene's P1 promoter but not at the P2 promoter. These studies demonstrate the existence of differential regulation of 11β-HSD1 expression in muscle cells through TNFα/p65 signalling and the P1 promoter, further enhancing our understanding of the role of 11β-HSD1 in the context of inflammatory disease.

Concentration dependence of Debye temperature in mixed K x Rb1−x Cl

Integrated intensities of Bragg reflections were measured with a triple-axis neutron spectrometer for powder samples of K x Rb1−x Cl for x = 0.5. The temperature factors were corrected for thermal diffuse scattering (TDS) and static contributions. The Debye temperature and the mean temperature factors obtained from these measurements are compared with the values obtained by other techniques and are found to be in good agreement. The Debye temperatures for RbCl (x = 0) and KCl (x = 1) determined by other authors were combined with these results and the concentration dependence of Θ in K x Rb1−x Cl, was found to be non-linear.

488 TULA for Bladder Tumours in a University Teaching Hospital: Outcomes Over a 2-Year Period

Aim

TULA (Transurethral laser ablation) of bladder tumours is a relatively non-invasive procedure that is carried out on a day-case basis under local anaesthesia, providing an attractive option for treating recurrent non-muscle invasive bladder cancer (NMIBC). However, data describing efficacy rates are limited.

Method

We carried out a retrospective audit of all TULA procedures carried out for bladder lesions between January 2018 and December 2019. Patients were identified using clinical coding and data collected using electronic case note data. Analysis was performed using Microsoft Excel.

Results

48 patients were identified, 75% were male and the average age was 77. Performance status (PS) was formally documented in 6 patients, with a median of 2.5. A total of 77 TULA procedures were identified. 7 patients had TULA as primary treatment, all but one of these patients had significant co-morbidities.

Biopsies were taken in 83% of procedures. Recurrence rate at 3 months was 29% (n=14). 18% (n=8) of patients went on to have repeat TULA and the remainder went on to have TURBT or biopsy and cystodiathermy. Of those patients with recurrence, 18% had disease progression. 1 patient required catheterisation and irrigation overnight, all other patients were discharged the same day. No patients required re-admission.

Conclusions

TULA is a safe, well tolerated procedure to treat low-grade, recurrent bladder tumours. It can also be used as a palliative procedure for high-grade lesions in patients with multiple co-morbidities. Future work includes collection of objective data on tolerance in the form of VAS pain scoring.

Occurrence of mild cognitive impairment with hyperinsulinaemia in Africans with advanced type 2 diabetes mellitus

There is paucity of information on the prevalence of mild cognitive impairment (MCI) among individuals with type 2 diabetes mellitus (T2DM) in sub-Saharan Africa, including Nigeria. In addition, the role of hyperinsulinaemia in the development of MCI needs further investigation. This study sought to assess cognition and hyperinsulinaemia, with the associated characteristics in patients with advanced T2DM. Cognition was assessed using Montreal cognitive assessment test (MoCA), while fasting plasma insulin was measured using an ELISA kit. Sixty one diabetic subjects and 32 non-diabetic controls, matched for age, gender and level of education were studied. The diabetics had MCI while the controls had normal cognitive function. About 88.5% of the diabetic subjects had MCI, in contrast with only 50% of the non-diabetic controls. The most significantly affected cognitive domains among the diabetics were executive function, naming, attention, abstraction and delayed recall. Among the diabetics, MCI correlated with age, weight and body mass index (BMI); and in addition, age and weight found to be significant predictors of MCI. Plasma insulin concentration among the diabetics (16.24 ± 13.5 µIU/ml) was more than twice that of the controls (7.59 ± 2.9 µIU/ml). Hyperinsulinaemia among the diabetics correlated with weight, BMI, blood pressure and fasting blood sugar (FBS). Glycated haemoglobin and FBS levels were higher among diabetics compared with the controls. In conclusion, Africans with advanced T2DM show multi-domain MCI with high prevalence, coexisting with hyperinsulinaemia. Majority of the patients have diabetic complications and poor glycaemic control. Hyperinsulinaemia may play a complementary role in the pathophysiology of MCI in T2DM.

•

Patients with advanced T2DM manifest multi-domain MCI with up to 88% prevalence.

•

There is hyperinsulinaemia coexisting with the MCI among patients with advanced 2DM.

•

Majority of the patients have diabetic complications and poor glycaemic control.